198 related articles for article (PubMed ID: 36497329)
1. Conventional vs. Drug-Eluting Beads Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma-A Propensity Score Weighted Comparison of Efficacy and Safety.
Savic LJ; Chen E; Nezami N; Murali N; Hamm CA; Wang C; Lin M; Schlachter T; Hong K; Georgiades C; Chapiro J; Laage Gaupp FM
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497329
[TBL] [Abstract][Full Text] [Related]
2. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of efficacy and safety of transarterial chemoembolization with CalliSpheres and conventional transarterial chemoembolization in treating unresectable intrahepatic cholangiocarcinoma patients.
Sun T; Zhang W; Chen L; Ren Y; Liu Y; Zheng C
J Cancer; 2022; 13(4):1282-1288. PubMed ID: 35281867
[No Abstract] [Full Text] [Related]
4. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.
Peng N; Mao L; Tao Y; Xiao K; Yuan G; He S
World J Surg Oncol; 2022 Aug; 20(1):254. PubMed ID: 35941634
[TBL] [Abstract][Full Text] [Related]
5. Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.
Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Hao Y; Zheng X; Li C; Li W
Cancer Biol Ther; 2022 Dec; 23(1):89-95. PubMed ID: 35230928
[TBL] [Abstract][Full Text] [Related]
6. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
[No Abstract] [Full Text] [Related]
7. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
8. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
9. DEB-TACE versus cTACE for unresectable HCC with B1-type bile duct invasion after successful biliary drainage: A propensity score matching analysis.
Fan W; Zheng X; Zhao X; Zhu B; Wu Y; Xue M; Tang R; Huang Z; Qiao L; Lu M; Tang Y; Wu J; Li J
Cancer Med; 2024 Jul; 13(13):e7419. PubMed ID: 38970348
[TBL] [Abstract][Full Text] [Related]
10. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model.
Do Minh D; Chapiro J; Gorodetski B; Huang Q; Liu C; Smolka S; Savic LJ; Wainstejn D; Lin M; Schlachter T; Gebauer B; Geschwind JF
Eur Radiol; 2017 Dec; 27(12):4995-5005. PubMed ID: 28677067
[TBL] [Abstract][Full Text] [Related]
11. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
Tang J; Huang Z; Xu J; Lv Q; Wang P
Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug-eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma.
Chen S; Yu W; Zhang K; Liu W; Chen C
Hepatol Res; 2021 Apr; 51(4):482-489. PubMed ID: 33462925
[TBL] [Abstract][Full Text] [Related]
13. Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS.
Fan W; Guo J; Zhu B; Wang S; Yu L; Huang W; Fan H; Li F; Wu Y; Zhao Y; Wang Y; Xue M; Wang H; Li J
Eur Radiol; 2021 Nov; 31(11):8291-8301. PubMed ID: 33893536
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres
Duan X; Liu J; Han X; Ren J; Li H; Li F; Ju S
Front Oncol; 2021; 11():793581. PubMed ID: 35127501
[TBL] [Abstract][Full Text] [Related]
15. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
Zhang ZS; Li HZ; Ma C; Xiao YD
BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
[TBL] [Abstract][Full Text] [Related]
16. Comparison of treatment efficacy and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres
Ma Y; Zhao C; Zhao H; Li H; Chen C; Xiang H; Zheng C; Ma C; Luo C; Qiu H; Yao Y; Hu H; Xiong B; Zhou J; Zhu H; Long Q
Am J Transl Res; 2019; 11(12):7456-7470. PubMed ID: 31934293
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients.
Lee IJ; Lee JH; Lee YB; Kim YJ; Yoon JH; Yin YH; Lee M; Hur S; Kim HC; Jae HJ; Chung JW
Ther Adv Med Oncol; 2019; 11():1758835919866072. PubMed ID: 31447948
[TBL] [Abstract][Full Text] [Related]
18. Comparison of CalliSpheres
Shi Z; Wang D; Kang T; Yi R; Cui L; Jiang H
Radiol Oncol; 2023 Mar; 57(1):70-79. PubMed ID: 36794998
[TBL] [Abstract][Full Text] [Related]
19. Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302.
Ikeda M; Arai Y; Inaba Y; Tanaka T; Sugawara S; Kodama Y; Aramaki T; Anai H; Morita S; Tsukahara Y; Seki H; Sato M; Kamimura K; Azama K; Tsurusaki M; Sugihara E; Miyazaki M; Kobayashi T; Sone M
Liver Cancer; 2022 Sep; 11(5):440-450. PubMed ID: 36158586
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Treatment for Unresectable Hepatocellular Carcinoma.
Chiu SH; Chang PY; Shih YL; Huang WY; Ko KH; Chang WC; Huang GS
Drug Des Devel Ther; 2020; 14():5029-5041. PubMed ID: 33235441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
